CONTE, Pierfranco
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 38.329
EU - Europa 15.866
AS - Asia 13.300
SA - Sud America 2.248
AF - Africa 236
OC - Oceania 34
Continente sconosciuto - Info sul continente non disponibili 14
Totale 70.027
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 38.043
GB - Regno Unito 5.475
CN - Cina 4.559
SG - Singapore 3.922
IT - Italia 2.981
HK - Hong Kong 2.001
BR - Brasile 1.853
SE - Svezia 1.505
DE - Germania 1.183
UA - Ucraina 1.101
FI - Finlandia 940
IE - Irlanda 919
VN - Vietnam 731
TR - Turchia 716
RU - Federazione Russa 636
BG - Bulgaria 386
KR - Corea 346
IN - India 240
FR - Francia 226
ID - Indonesia 195
AR - Argentina 136
CA - Canada 121
MX - Messico 100
NL - Olanda 90
BD - Bangladesh 80
IQ - Iraq 76
EC - Ecuador 75
JP - Giappone 73
ZA - Sudafrica 71
BE - Belgio 69
PL - Polonia 69
ES - Italia 52
CO - Colombia 41
LT - Lituania 40
PY - Paraguay 40
UZ - Uzbekistan 35
VE - Venezuela 35
AE - Emirati Arabi Uniti 34
AU - Australia 34
PK - Pakistan 33
MA - Marocco 32
MY - Malesia 32
CL - Cile 30
AT - Austria 29
IR - Iran 27
EG - Egitto 25
AL - Albania 22
SA - Arabia Saudita 22
HU - Ungheria 21
KE - Kenya 21
CZ - Repubblica Ceca 20
PH - Filippine 19
NP - Nepal 18
JO - Giordania 16
RO - Romania 16
UY - Uruguay 16
DZ - Algeria 14
IL - Israele 14
TN - Tunisia 14
TW - Taiwan 14
CH - Svizzera 13
DO - Repubblica Dominicana 13
GR - Grecia 13
AZ - Azerbaigian 11
BO - Bolivia 11
ET - Etiopia 10
EU - Europa 10
KZ - Kazakistan 10
NG - Nigeria 10
PE - Perù 10
HN - Honduras 9
OM - Oman 9
SK - Slovacchia (Repubblica Slovacca) 9
PA - Panama 8
RS - Serbia 8
AM - Armenia 7
BW - Botswana 7
JM - Giamaica 7
KG - Kirghizistan 7
LB - Libano 7
TH - Thailandia 7
MK - Macedonia 6
SI - Slovenia 6
AO - Angola 5
BH - Bahrain 5
DK - Danimarca 5
NI - Nicaragua 5
PT - Portogallo 5
BZ - Belize 4
CI - Costa d'Avorio 4
CR - Costa Rica 4
GE - Georgia 4
KW - Kuwait 4
MD - Moldavia 4
MN - Mongolia 4
NO - Norvegia 4
SN - Senegal 4
TT - Trinidad e Tobago 4
A2 - ???statistics.table.value.countryCode.A2??? 3
AF - Afghanistan, Repubblica islamica di 3
Totale 69.963
Salva come PNG Salva come JPEG
Città #
Fairfield 4.172
Southend 3.802
Woodbridge 3.069
Santa Clara 2.711
Ashburn 2.630
Houston 2.617
Singapore 2.468
Jacksonville 2.283
Chandler 2.036
Hong Kong 1.986
Ann Arbor 1.736
Dearborn 1.571
Seattle 1.527
Hefei 1.524
Wilmington 1.516
Cambridge 1.375
London 926
Dublin 916
Nyköping 827
Beijing 815
Modena 630
Los Angeles 562
Helsinki 560
Chicago 528
The Dalles 451
Princeton 444
San Diego 423
Sofia 380
Eugene 379
San Jose 371
Izmir 363
Seoul 324
New York 319
Ho Chi Minh City 290
Council Bluffs 245
Milan 232
Salt Lake City 215
Des Moines 201
Moscow 194
Shanghai 192
Buffalo 191
São Paulo 179
Columbus 156
Jakarta 144
Rome 143
Falls Church 142
Dallas 137
Munich 136
Hanoi 135
Boardman 117
Elk Grove Village 116
Tampa 107
Norwalk 92
Bologna 88
Guangzhou 74
Frankfurt am Main 72
Brussels 65
Lancaster 63
Phoenix 58
Redwood City 57
Atlanta 55
Dong Ket 54
Rio de Janeiro 52
Sterling 52
Fremont 51
Turin 51
Naples 50
Warsaw 50
Bremen 49
Denver 49
Tokyo 49
Kunming 48
Nanjing 47
Redondo Beach 47
Belo Horizonte 46
Porto Alegre 45
Brooklyn 40
Kilburn 38
Florence 37
Brasília 36
Mexico City 36
Orem 36
Stockholm 36
Bari 35
Chennai 35
San Mateo 34
Curitiba 33
Hounslow 33
Turku 33
Montreal 31
Tashkent 31
Verona 31
Zhengzhou 31
Boston 30
Nuremberg 30
Wuhan 30
Da Nang 28
Dulles 28
Guayaquil 28
Johannesburg 28
Totale 51.665
Salva come PNG Salva come JPEG
Nome #
VALORE PROGNOSTICO E PREDITTIVO DI p53 NEL CARCINOMA MAMMARIO TRATTATO CON CHEMIOTERAPIA NEOADIUVANTE 1.036
ShortHER: TRATTAMENTO ADIUVANTE CON HERCEPTIN PER 3 MESI VERSO 12 MESI, IN ASSOCIAZIONE CON DUE DIFFERENTI REGIMI DI CHEMIOTERAPIA, NELLE PAZIENTI CON CARCINOMA MAMMARIO HER2 POSITIVO 446
Magnetic Resonance Imaging and Ultrasonography in Predicting Infiltrating Residual Disease after Preoperative Chemotherapy in Stage II-III Breast Cancer 397
Rigenerand srl - Spin off Università di Modena e Reggio Emilia 388
MSC-delivered soluble TRAIl and paclitaxel as novel combinatory treatment for pancreatic adenocarcinoma 384
Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management 380
GMP-manufactured density gradient media for optimized mesenchymal stromal/stem cell isolation and expansion. 374
Cytogenetic abnormalities and clinical features in a patient cohort affected by three or more synchronous or metachronous primitive malignancies. 374
A Dose-finding and Biomarker Evaluation Phase Ib Study of Everolimus in Association With 5-Fluorouracil and Pelvic Radiotherapy as Neoadjuvant Treatment of Locally Advanced Rectal Cancer (E-LARC Study) 363
9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study. 358
Soluble TRAIL Armed Human MSC As Gene Therapy For Pancreatic Cancer 354
Predictors of human epidermal growth factor receptor 2 fluorescence in-situ hybridisation amplification in immunohistochemistry score 2+ infiltrating breast cancer: a single institution analysis. 353
MSC and Tumors: Homing, Differentiation and Secretion Influence The Therapeutic Potentials 353
Prognostic value of Dworak grade of regression (GR) in patients with rectal carcinoma treated with preoperative radiochemotherapy 348
Neoadjuvant treatment with Single – Agent Cetuximab Followed by 5-Fu, Cetuximab, and Pelvic Radiotherapy: A Phase II Study in Locally Advanced Rectal Cancer. 341
SOLUBLE TRAIL-ARMED HUMAN AD-MSC AS NOVEL CELL THERAPY APPROACH FOR PANCREATIC DUCTAL ADENOCARCINOMA 338
Letrozole Versus Letrozole Plus Lapatinib (GW572016) in Hormone-Sensitive, HER2-Negative Operable Breast Cancer: A Double-Blind, Randomized Phase II Study with Biomarker Evaluation (EGF109077-LAP107692/LETLOB) 337
A novel anti-GD2/4-1BB chimeric antigen receptor triggers neuroblastoma cell killing 337
Lack of benefit of maintenance paclitaxel in first-line chemotherapy in metastatic breast cancer 331
Phase II, randomized trial of preoperative epirubicin-paclitaxel +/- gefitinib with biomarker evaluation in operable breast cancer. 328
Mutational Profile of Metastatic Breast Cancer Tissue in Patients Treated with Exemestane Plus Everolimus 327
Le Cellule Staminali Mesenchimali: Aspetti Biologici ed Approcci Terapeutici 324
Posterior reversible encephalopathy syndrome during ipilimumab therapy for malignant melanoma 318
MODULAZIONE DELL’ESPRESSIONE DI BIOMARCATORI E PROGNOSI IN PAZIENTI AFFETTE DA CARCINOMA MAMMARIO OPERABILE SOTTOPOSTE A CHEMIOTERAPIA PREOPERATORIA 317
Mesenchymal progenitors aging highlights a mir-196 switch targeting HOXB7 as master regulator of proliferation and osteogenesis 314
Isolation, characterization, and transduction of endometrial decidual tissue multipotent mesenchymal stromal/stem cells from menstrual blood 314
A prognostic model based on nodal status and Ki-67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy 312
Proteasome inhibitors sensitize colon carcinoma cells to TRAIL-induced apoptosis via enhanced release of Smac/DIABLO from the mitochondria 306
Phase I study of intraperitoneal MHC unrestricted adoptive cell therapy with TALL-104 cells in patients with peritoneal carcinosis 305
Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial . 301
Animal serum-free culture conditions for isolation and expansion of multipotent mesenchymal stromal cells from human BM 301
Mesenchymal progenitors expressing TRAIL induce apoptosis in sarcomas 298
Achievements and unmet needs in the management of advanced ovarian cancer 295
FOLFOX6 and bevacizumab in non-optimally resectable liver metastases from colorectal cancer 295
CHER LOB Trial: Preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2-positive operable breast cancer--Safety report as per Independent Data Monitoring Committee (IDMC) and preliminary activity data 291
Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer. 290
METHOD FOR PRODUCTION OF ANTI-TUMOR TRAIL PROTEIN 289
Clinical and molecular predictors of long-term response in HER2 positive metastatic breast cancer patients. 289
Predictive and prognostic role of p53 according to tumor phenotype in breast cancer patients treated with preoperative chemotherapy: a single-institution analysis 289
Epidermal growth factor receptor gene copy number, K-ras mutation and pathological response to preoperative cetuximab, 5-FU and radiation therapy in locally advanced rectal cancer.. 284
3* Final analysis of the phase III multicentric Italian study Short-HER: 9 weeks vs 1 year adjuvant trastuzumab for HER2+ early breast cancer 281
Restoration and reversible expansion of the osteoblastic hematopoietic stem cell niche after marrow radioablation 280
Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single Institution analysis 276
Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer 274
A prognostic model based on nodal status and Ki 67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy 273
Immune characterization of breast cancer metastases: prognostic implications. 273
Laparoscopic approach of gastric gastrointestinal stromal tumors (GISTs): Is it still a courageous choice? Report of two cases 272
Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial 269
Prognostic and Predictive Value of Baseline and Posttreatment Molecular Marker Expression in Locally Advanced Rectal Cancer Treated With Neoadjuvant Chemoradiotherapy 269
Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study 267
Final results of a phase II randomized trial of neoadjuvant anthracycline-taxane chemotherapy plus lapatinib, trastuzumab, or both in HER2-positive breast cancer (CHER-LOB trial). 263
A phase I-II study of oral doxifluridine plus radiotherapy in radiosensitive tumors of the pelvic region. 259
Double-blind, placebo-controlled, multicentric randomized phase IIb neoadjuvant study of letrozole-lapatinib in postmenopausal HER2-negative, hormone receptor-positive operable breast cancer 259
Preoperative chemotherapy plus lapatinib or trastuzumab or both in Her2 positive operable breast cancer. EGF109085-LAP106988/CHERLOB Trial. 259
Q-TWiST analysis of ixabepilone in combination with capecitabine on quality of life in patients with metastatic breast cancer 258
Donor Cell-Derived Osteopoiesis Originates from a Self-Renewing Stem Cell with a Limited Regenerative Contribution after Transplantation 258
9 Weeks vs 1 Year Adjuvant Trastuzumab in Combination with Chemotherapy: Preliminary Cardiac Safety Data of the Phase III Multicentric Italian Study Short-HER. 256
Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients 255
Significance of lymph node sampling in epithelial carcinoma of the ovary. 253
A dose-finding study of ifosfamide by three-day continuous infusion in pretreated, advanced breast cancer patients. 251
Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: final results of After-6 protocol 1 247
Incidence and clinical impact of sterilized disease and minimal residual disease after preoperative radiochemotherapy for rectal cancer 245
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation 245
Ki67 as a Predictor of Response and Long Term Survival in Hormone Receptor Positive/HER2 Negative Breast Cancer Patients Treated with Preoperative Chemotherapy 238
Prognostic role of EGFR gene copy number and KRAS mutation in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy. 237
Prognostic value of "Dworak" tumor regression grade (TRG) after pre-operative chemo-radiotherapy in rectal cancer (RC) 235
Magnetic resonance imaging and ultrasonography in predicting pathologic extent after preoperative chemotherapy in stage II-III breast cancer 235
Gastrointestinal stromal tumor and other primary metachronous and synchronous neoplasms as a suspicious criterion for syndromic setting 234
Cardiotoxicity of Epirubicin/Paclitaxel Containing Regimens: Role of Cardiac Risk Factors 233
Primary adrenal gland carcinosarcoma associated with metastatic rectal cancer: a hitherto unreported collision tumor 233
Erratum to: Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2− breast cancer: results from two prospective trials (Breast Cancer Research and Treatment, (2017), 163, 2, (295-302), 10.1007/s10549-017-4191-y) 232
PREVALENCE OF NODE NEGATIVE AND SMALL SIZE TUMORS IN A NATIONAL, RANDOMISED, PHASE III ADJUVANT TRIAL IN HER2 + EARLY BREAST CANCER (SHORT-HER STUDY) 231
Rare breast cancer subtypes: Histological, molecular, and clinical peculiarities 230
Intraperitoneal versus Intravenous Cisplatin in Combination with Intravenous Cyclophosphamide and Epidoxorubicin in Optimally Cytoreduced Advanced Epithelial Ovarian Cancer: A randomized trial of the Gruppo Oncologico Nord Ovest. 229
Bevacizumab and osteonecrosis of the jaw: Incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer 229
Preliminary safety data of preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2-positive operable breast cancer 227
Timing for starting second-line therapy in recurrent ovarian cancer 227
Paclitaxel and vinorelbine in anthracycline pretreated breast cancer: a phase II study. 225
Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer. 225
Primary Systemic Therapy in operable breast cancer: clinical data and biological fall-out 224
PROLIFERATION AND APOPTOSIS BEFORE AND AFTER PRIMARY SYSTEMIC THERAPY FOR OPERABLE BREAST CANCER 224
Activity of first-line epirubicin and paclitaxel in metastatic breast cancer is independent of type of adjuvant therapy 223
Device for cell culture 221
Biomarkers predicting clinical benefit: fact or fiction? 217
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. 216
A phase II study with danazol in metastatic breast cancer. 216
Randomized phase III trials of adjuvant FAMTX or FEMTX compared with surgery alone in resected gastric cancer. A combined analysis of the EORTC GI Group and the ICCG 214
Preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2 positive operable breast cancer: results of the randomized phase II CHER-LOB study 214
Analysis of Bevacizumab (Bev) Therapy, Bisphosphonate Use and Osteonecrosis of the Jaw (ONJ) in >1900 Patients Treated in Two Randomized, Controlled Trials 212
Evolving nonendocrine therapeutic options for metastatic breast cancer: how adjuvant chemotherapy influences treatment. 210
Change in HER2 Status in HER2 Positive Operable Breast Cancer Patients Treated with Neoadjuvant Chemotherapy with or without Anti-HER2 Therapy: Analysis of Two Consecutive Cohorts 210
Severe 5-fluorouracil toxicity associated with a marked alteration of pharmacokinetics of 5-fluorouracil and its catabolite 5-fluoro-5,6-dihydrouracil: A case report 209
Treatment of large HCC: transcatheter arterial chemoembolization combined with percutaneous ethanol injection versus repeated transcatheter arterial chemoembolization. 208
Trans-CHER-Lob: A Biomarker Analysis of the Randomized Phase II Study of Neoadjuvant Chemotherapy Plus Trastuzumab, Lapatinib or Combined Trastuzumab and Lapatinib in HER2 Positive Operable Breast Cancer. 208
CHER-LOB: PREOPERATIVE CHEMOTHERAPY PLUS TRASTUZUMAB, LAPATINIB OR BOTH IN HER2-POSITIVE OPERABLE BREAST CANCER – PRELIMINARY SAFETY REPORT WITH FOCUS ON CARDIAC TOLERABILITY 208
In response to Body letter to the editor regarding "Safety of intravenous and oral Bisphosphonates and compliance with dosing regimens" 207
Single agent epirubicin as first line chemotherapy for metastatic breast cancer patients 204
Triple-negative breast cancer: current management and future options. 204
High – dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study 204
Biweekly chemotherapy with oxaliplatin, irinotecan, infusional fluorouracil, and leucovorin: A pilot study in patients with metastatic colorectal cancer 203
Totale 28.177
Salva come PNG Salva come JPEG
Categoria #
all - tutte 279.829
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 279.829
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20213.307 0 0 0 0 0 0 617 874 264 846 396 310
2021/20226.219 88 931 783 382 147 259 445 325 648 469 962 780
2022/20236.351 741 573 316 510 659 906 77 541 1.521 83 257 167
2023/20243.774 182 248 204 229 705 349 393 705 125 114 163 357
2024/202511.504 362 159 183 872 2.139 1.812 493 761 1.480 780 1.022 1.441
2025/202613.815 1.329 1.003 2.221 3.016 3.369 2.034 843 0 0 0 0 0
Totale 70.392